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ABSTRACT
Background: According to the World Health Organisation, tobacco use is one of the most widespread 
public health threats in the world, making it particularly urgent to promote smoking cessation. The ef-
fectiveness of pharmacist interventions in smoking cessation has been documented in the international 
literature, but not sufficiently in Portugal. Objective: To report the preliminary results of study to assess 
the effectiveness of a smoking cessation programme delivered in Portuguese community pharmacies 
using an outsorcing-based regimen. Methods: Within the scope of a pharmaceutical care programme 
implemented in seven community pharmacies by an outsourced pharmacist, a specific consultation 
for smoking cessation was developed, in accordance with Portugal’s General Directorate of Health’s 
recommendations and instruments. The smokers were identified and invited to join the programme 
by the pharmacy staff during their daily activities. Patients that accepted signed an informed consent. 
Through several face-to-face and phone consultations and based on a comprehensive patient approach, 
personalised plans to quit tobacco were defined with the patients’ agreement. The effectiveness of the 
service was assessed through the evaluation of quit rates at 1, 6 and 12 months. The continuous variables 
were expressed as mean ± standard error of the mean. Results: During approximately 5 years (between 
January 2009 and July 2014), 69 smokers joined the programme. Of these, 17 desisted during the first 
consultation. Of the remaining 52 patients, the mean age was 47.4 ± 2.11 years old and 55.8% were 
male. A total of 264 pharmaceutical consultations were delivered and, on average, each patient received 
7.7 ± 0.81 interventions. Most interventions (60.1%) were pharmacological (e.g. nicotine replacement 
products), while non-pharmacological measures (e.g. motivational interviewing) represented 39.9%. Five 
patients were referred to a physician. At 1 month after the quit date, 37 patients were abstinent (53.6%); 6 
months later the number reduced to 24 (34.8%) and, 1 year later, 16 patients remained abstinent (23.2%). 
Conclusions: The implementation of a smoking cessation programme in community pharmacies using 
an external pharmacist may contribute effectively to tobacco cessation in Portugal. 
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INTRODUCTION
According to the World Health Organisation, 
the tobacco epidemic is one of the greatest public 
health threats the world has ever faced, killing 
nearly six million people a year(1). Additionally, it is 
estimated that if effective measures are not urgently 
taken, tobacco could kill over 1 billion people in 
the 21st century. In Portugal, tobacco use may be 
responsible for 1 in 10 deaths of adult smokers and 
1 in 4 for people aged 45–59 years old(2). Approxi-
mately half of the Portuguese smokers never made 
any attempt to stop smoking(3).
The effectiveness of pharmacist interventions in 
smoking cessation is recognised in the international 
literature(4-6), but, in Portugal, the data are scarce. 
This paper reports the preliminary results of a 
study aiming to assess the effectiveness of a smok-
ing cessation programme delivered in Portuguese 
community pharmacies using an outsorcing-based 
regimen.
METHODS
A retrospective and longitudinal study on 
the preliminary results of a pharmaceutical care 
programme for smoking cessation is reported. 
An outsourced (external) pharmacist, specifically 
trained in smoking cessation, implemented the 
pharmaceutical care programme in seven commu-
nity pharmacies (mainly in the Algarve and Alentejo 
Portuguese regions), following Portugal’s General 
Directorate of Health’s recommendations (through 
several consultations and phone contacts)(7). The 
patients were identified during the daily pharmacy 
activities with no specific sampling method other 
than having smoking habits and wish to quit smok-
ing. They were invited to join the programme by 
the pharmacy staff (pharmacists or technicians) and 
were informed about the structure of the service 
and the price of the consultations. All patients that 
joined the service signed an informed consent form.
In the first consultation, and using a specific 
form, the pharmacist recorded tobacco habits, a 
RESUMEN
Antecedentes: Según la Organización Mundial de la Salud, el tabaco es una de las mayores amena-
zas del mundo, siendo urgente promover el abandono tabáquico. La efectividad de las intervenciones 
farmacéuticas en cesación tabáquica ha sido documentada en la literatura, pero no en Portugal. Objetivo: 
Comunicar los resultados preliminares de un estudio para evaluar la efectividad de un programa de ce-
sación tabáquica desarrollado en farmacias comunitarias portuguesas usando un régimen de out-sourcing. 
Métodos: En el ámbito de un programa de atención farmacéutica implantado en siete farmacias por un 
farmacéutico externalizado, se desarrolló una consulta de cesación tabáquica siguiendo las recomenda-
ciones e instrumentos de la Dirección General de Salud de Portugal. Se identificó a los fumadores y el 
personal de la farmacia durante sus actividades rutinarias les invitó a unirse al programa. Los que aceptaban 
firmaban un consentimiento informado. Mediante consultas presenciales y telefónicas y a través de un 
abordaje global del paciente, se definieron en acuerdo con el paciente planes personalizados de abandono 
del tabaquismo. La efectividad del servicio se midió mediante las tasas de cesación a 1, 6 y 12 meses. 
Las variables continuas se expresaron como media ± error estándar de la media. Resultados: Durante 
aproximadamente 5 años (entre enero 2009 y julio 2014), 69 fumadores se unieron al programa. De es-
tos, 17 desistieron durante la primera consulta. Entre los restantes 52 pacientes, tenían 47.4 ± 2.11 años 
y el 55,8% eran hombres. Se realizaron 264 consultas farmacéuticas y, en media cada paciente recibió 7.7 
± 0.81 intervenciones. La mayoría de las intervenciones (60,1%) eran farmacológicas (p.e. productos de 
substitución de nicotina), y el restante 39,9% fueron medidas no farmacológicas (p.e. entrevista motivacio-
nal). Cinco pacientes fueron remitidos al médico.  Después de 1 mes de la fecha convenida para el inicio 
de la cesación, 37 pacientes (53,6%) estaban en abstinencia; 6 meses más tarde el número se reducía a 24 
(34,8%) y un año más tarde 16 pacientes (23,2%) permanecían abstinentes.Conclusión: La implantación 
de un programa de casación tabáquica en farmacias comunitarias, utilizando un farmacéutico externo, 
puede contribuir efectivamente a la cesación tabáquica en Portugal.
Palabras clave: Farmacéutico; Cesación tabáquica; Farmacia comunitaria; Atención farmacéutica
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clinical history and the medication profile. All 
consultations included an assessment of the body 
mass index, waist circumference, blood pressure 
and respiratory parameters, such as spirometric 
tests and carbon monoxide and carboxihaemoglo-
bin in exhaled air. The two later were considered 
as tobacco biomarkers. The Richmond(8), and 
Fagerström(9) scales were used to evaluate quit 
motivation and nicotine dependence, respectively. 
Based on a comprehensive patient approach, the 
pharmacist suggested a therapeutic plan to quit 
tobacco (pharmacological and non-pharmacological 
interventions). Nicotine replacement products, 
medication adherence and induction of prescription 
medicinal products were the main pharmacological 
interventions. Non-pharmacological interventions 
were motivational interviewing, and the promotion 
of strategies to reduce the number of cigarettes and 
to avoid concomitant risk factors. The interven-
tions were directed both to patients or physicians. 
Referral to a physician occurred when diagnosis of 
a medical condition was required or when:
- Treatment with nicotine replacement products 
was inadequate.
- Spirometry was outside the normal values, 
without positive evolution from smoking ces-
sation.
- An uncontrolled mental disease and/or another 
addiction were present.
- Strategies involving non-prescription medicines 
were exhausted.
In follow-up consultations and phone calls, all 
the pharmacist’s interventions were evaluated and 
the therapeutic plan adjusted (if needed) until to 
achieve tobacco abstinence. Patients could leave 
the programme at any time and return later if a 
relapse occurred.
The effectiveness of pharmacist interventions 
was assessed by smoking cessation at endpoints: 1, 
6 and 12 months after the patient’s quit date. Mean 
values were expressed as mean ± standard error of 
the mean.
RESULTS
Between January 2009 and July 2014, 69 smok-
ers joined the smoking cessation programme in the 
seven community pharmacies enrolled. Thirty-
seven (53.6%) of these were male. The mean age 
was 46.3 ± 1.80 years old and the majority (50.7%) 
of smokers belonged to the age group between 
40 and 64 years old. The upper-secondary school 
was the most prevalent educational level (49.3%). 
Almost 70.0% of the patients declared an active 
working situation. Table 1 shows an overview of 
patients’ characteristics and tobacco habits. Dur-
ing the first consultation, 24.6% of the patients 
abandoned the programme. Of the remaining 52 
smokers, 29 (55.8%) were male, with a mean age 
of 47.4 ± 2.11 years old. Among the patients, 48.1% 
had an upper-secondary education level, and 67.3% 
were actively employed. Dyslipidaemia (71.2%), 
overweight (61.5%) and anxiety (44.2%) were the 
most prevalent comorbidities (Table 1). 
Table 1. Overview of enrolled patients’ characteristics 
and tobacco habits.
Total Baseline
Number 69 52
Gender (%)
Male 37 (53.6) 29 (55.8)
Female 32 (46.4) 23 (44.2)
Age (mean ± standard error) 46.3±1.80 47.4±2.11
Age group
< 40 26 (37.7) 18 (34.6)
40-64 35 (50.7) 27 (51.9)
≥ 65 8 (11.6) 7 (13.5)
Education level (%)
No education 2 (2.9) 2 (3.8)
Compulsory education 1st–9th years 21 (30.4) 13 (25.0)
Upper-secondary 34 (49.3) 25 (48.1)
Higher education 12 (17.4) 12 (23.1)
Tobacco habits (mean ± standard error)
Age at initial tobacco use 16.4±0.58 15.8±0.59
Number of cigarettes per day 20.6±1.53 21.2±1.93
Time spent in tobacco consumption 29.2±1.80 30.1±2.21
The figures below show the socio-demographic profile and to-
bacco habits of patients included in the total sample of those who 
joined the smoking cessation programme and in the sample of 
those who continued after the first consultation (baseline).
During the study period, 264 pharmaceutical 
consultations were performed, 5.2 ± 0.51 on aver-
age per patient, with a mean time for face-to-face 
follow-up consultations of 5.5 ± 0.76 months. 
According with the information registered at the 
first pharmaceutical consultation, in average, each 
45Smoking ceSSation in a community pharmacy: preliminary reSultS of a pharmaceutical care programme
patient initiated tobacco use very early (at 15.8 ± 
0.59 years old) and consumed about 21.2 ± 1.93 
cigarettes per day. A mean smoking time of 30.1 
± 2.21 years was registered (Table 1). Previous 
attempts to quit smoking were reported by 35 
smokers (67.3%). More than 40% of the patients 
showed moderate motivation, and their nicotine 
dependence was classified as primarily low or me-
dium (63.5%).
A total of 401 interventions were provided (7.7 
± 0.81 on average per patient), 395 (98.8%) were 
addressed to patients and 5 (1.3%) addressed to phy-
sicians. Pharmacological interventions represented 
60.1% (n=241) of the total provided. Fifty patients 
(96.2%) decided to quit tobacco with the support 
of pharmacological methods. Nicotine replacement 
products were recommended in 92.0% of the cases. 
Oral pharmaceutical forms were the most utilised 
forms, while 13 patients used a combination therapy 
with transdermal delivery. Varenicline and Bupro-
prion were prescribed to 6 patients, 1 before the 
patient joined the programme and the others after 
the pharmacist’s referral. Anxiolytic therapy was re-
quired for 20 patients (40.0%), including prescribed 
medication or phytotherapy (non-prescription me-
dicines). The most frequent non-pharmacological 
interventions were motivational interviewing used 
with all the patients, promoting the avoidance of risk 
factors (98.1%) and the reduction of daily cigaret-
tes (42.3%). Table 2 summarized the pharmacist’s 
interventions.
One month after patient’s quit date, 37 of the 
initial 69 smokers had stopped smoking (53.6%). 
The quit rate decreased to 34.8% after 6 months 
and to 23.2% after 1 year. Figure 1 shows the flow 
of patients during the study and respective quit 
smoking rates.
At baseline, 69 smokers joined the smoking ces-
sation programme (stippled area). Of these, 17 aban-
doned the programme during the first consultation. 
Of the 52 patients continuing in the programme, 13 
reduced their number of cigarettes per day but drop-
ped out before recording a quit date. Thirty-nine 
smokers recorded their quit date, with 2 relapsing 
before 1 month. Thus, 37 patients from the initial 
sample achieved abstinence 1 month after the quit 
date or 53.6% (vertical lines). Of these, 8 dropped 
out. Of the 29 remaining patients, 3 relapsed, and 
2 patients had only 4 months of follow-up sessions. 
This means that 24 patients were still abstinent 6 
months after their quit date or 34.8% (horizontal 
lines). Seven of these dropped out. Of the 17 patients 
that continued in the service, 16 patients remained 
abstinent for twelve months after their quit date or 
23.2% (white area). Note: AB = abstinent patients
Table 2 – Description of the pharmacist’s interventions
Interventions
Patients
Number %
Non-pharmacological 52 100
Motivational approach 52 100
Avoidance of tobacco consumption risk factors 51 98.1
Reduction of the cigarettes’ number 22 42.3
Electronic cigarette 4 7.7
Changes in tobacco brand name 2 3.8
Pharmacological 50 96.2
Nicotine replacement products:
Gums 9 18.0
Patches 6 12.0
Lozenges 16 32.0
Patches followed by gums 3 6.0
Gums followed by patches 5 10.0
Lozenges followed by patches 3 6.0
Gums and patches (combined therapy) 2 4.0
Varenicline 3 6.0
Varenicline and bupropion 1 2.0
Varenicline followed by gums 1 2.0
Varenicline and lozenges 1 2.0
Anxiolytic therapy 20 40.0
 6 months 1 month Baseline 12 months 
69 Smokers 37 AB 24 AB 16 AB 
Figure 1. Flow of patients during the study and 
respective quit rates
DISCUSSION
Our study demonstrated that there is room to 
implement effective smoking cessation programs 
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in Portuguese community pharmacies. The rela-
tive small number of smokers in our study may 
be due to lack of awareness of smoking cessation 
programmes assisted by a pharmacist, allied with 
a weak involvement of the pharmacies in tobacco 
control policies in Portugal.
The prevalence of tobacco use in Portugal and, 
in particular, in the Algarve and Alentejo regions is 
higher among males than females, showing a trend 
towards decreasing among men(10). This may ex-
plain the higher percentage of male patients in our 
sample, in spite of females being found to be more 
receptive to asking for help to quit smoking(11). The 
most prevalent age group in our sample matches the 
distribution of smokers in Portugal(10). 
Our programme presented better cessa-
tion effectiveness rates than reported in the lit-
erature(4-6,12,13). Our quit rate of 53.6% after 1 
month compares favourably with quit rates ranging 
from 22%(12) to 26%(5), and our quit rate of 34.8% 
after 6 months of abstinence is still higher than 
the previously reported quit rates of 25%(13) and 
28%(6). Disappointing quit rates of 3.6% by 1 year 
after the quit date in other studies(12) contrast 
with our 23.2% quit rate. Our high success rates 
may be due to the close relationship established 
between the patients and the pharmacist and his 
easy availability (pharmacy and phone contacts). In 
addition, the measurement of several health param-
eters during consultations, namely spirometry and 
carbon monoxide tests, may have contributed also 
to additional motivation. However, we believe that 
a highly trained pharmacist who was focused on 
providing this service, as the specialized outsourced 
pharmacist, could result in substantial improve-
ments in smoking cessation rates, also explaining 
our better outcomes. 
A potential limitation of our study is the reduced 
number of patients and locations, what precluded 
generalization of the results. However, these pre-
liminary results encourage us to proceed towards 
the main study with an increase in the number of 
patients and locations.
CONCLUSION
Based on these preliminary results, the imple-
mentation of an outsourced smoking cessation 
programme in community pharmacies using a 
highly-trained external pharmacist may contribute 
effectively to tobacco cessation in Portugal. 
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